Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project

Kardiologia Polska

Volumn 71, Issue 7, 2013, Pages 702-711

  Sovi, Nevena ^a   Pajk, Andrzej ^a   Jankowski, Piotr ^a   Duenas, Alejandra ^b   Kawecka Jaszcz, Kalina ^a   Wolfshaut Wolak, Renata ^a   Stepaniak, Urszula ^a   Kawalec, Paweł ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b IESEG SCHOOL OF MANAGEMENT   (France)

Author keywords

Cardiovascular disease; Cost effectiveness; EUROACTION project; Primary prevention

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGH RISK PATIENT; HYPERTENSION; LIPID BLOOD LEVEL; NURSING CARE; POLAND; PREVENTIVE MEDICINE; PROBABILITY; RISK ASSESSMENT; SEX DIFFERENCE; SMOKING;

EID: 84880803641     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0157     Document Type: Article

References (23)

1. World Health Organization, Regional Office for Europe, European health for all database, 2010.
2. Pachocki R, Banasiak W, Jaworski R. Cost of coronary artery disease (CAD) in Poland. 2008. [Poster presentation] International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress, November 8-11 2008, Athens, Greece.
3. Pajk A, Szafraniec K, Janion M et al.; for a POLCARD study group. The impact of the national Program of Cardiovascular Disease Prevention (PCVDP) on the quality of primary CVD prevention in clinical practice. Kardiol Pol, 2010; 68: 1332-1340.
4. Wood DA, Kotseva K, Jennings C et al. EUROACTION: a European Society of Cardiology demonstration project in preventive cardiology. Summary of design, methodology and outcomes. Eur Heart J Suppl, 2004; 6 (suppl. J): J3.
5. Wood DA, Kotseva K, Connolly S et al.; on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet, 2008; 371: 1999-2012.
6. Anderson KM, Odell PM, Wilson PWF et al. Cardiovascular disease risk profiles. Am Heart J, 1991; 121: 293-298.
7. Ward S, Lloyd Jones M, Pandor A et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 2007; 11: 1-160.
8. Central Statistical Office of Poland, branch yearbook. Demographic Yearbook of Poland 2009. Central Statistical Office, Warsaw 2009.
9. Polonski L, Gsior G, Gierlotka M et al. Polish Registry of Acute Coronary Syndromes (PL-ACS). Caracteristics, treatments and outcomes of patients with acute coronary syndromes in Poland. Kardiol Pol, 2007; 65: 861-872.
10. Zipes DP, Camm AJ, Borggrefe M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Europace, 2006; 8: 746.
11. Chmiel AL, Wierzbicka-Chmiel JD. Sudden cardiac death-an assessment of pre-hospital proceedings. Wiad Lek, 2007; 60: 396.
12. Kind P, Dolan P, Gudex C et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ, 1998; 316: 736.
13. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Commun Health, 2003; 57: 622.
14. Lenzen M. Scholte op Reimer W, Norekval TM et al. Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Eur J Cardiovasc Nurs, 2006; 5: 115-121.
15. Ara R, Tumur I, Pandor A et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technol Assess, 2008; 12: 1-232.
16. Latour-Perez J, de Miguel BE, Betegon L, Badia X. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis. Value Health, 2008; 11: 853-861.
17. Pignone M, Earnshaw S, Tice JA et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med, 2006; 144: 326-336.
18. Visser K, Kuntz KM, Donaldson MC et al. Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. J Vasc Interv Radiol, 2003; 14: 53-62.
19. Golicki D, Niewada M, Jakubczyk M et al. Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study. Pol Arch Med Wewn, 2010; 120: 276-281.
20. Golicki D, Jakubczyk M, Niewada M et al. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health, 2010; 13: 289-297.
21. Wonderling D, Langham S, Buxton M et al. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses. BMJ, 1996; 312: 1274-1278.
22. Rasmussen SR, Thomsen JL, Kilsmark J et al. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs. Scand J Public Health, 2007; 35: 365-372.
23. Daly CA, Stepinska J, Deptuch T et al. Differences in presentation and management of Stable Angina from East to West in Europe: A comparison between Poland and the UK. Int J Cardiol, 2008; 125: 311-318.